Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matteo Megna

Showing results (231-240 of 251) with videos related to

Pageof 26
Sort By:
Dermatology and Therapy|June 9, 2026
Real-World Long-Term Effectiveness and Safety of Secukinumab in Psoriasis: Up to 7 Years of Evidence from the Italian Landscape Psoriasis (IL PSO) Multicenter Retrospective StudyLuciano Ibba, Sara Di Giulio, Piergiorgio Malagoli, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|May 14, 2026
Treatment-associated phenotype switching between psoriasis and atopic dermatitisTiago Torres, Mario Valenti, Anna Balato, et al.
Dermatology and Therapy|March 17, 2026
Short-Term Effectiveness and Safety of Deucravacitinib in Psoriasis: A Multicenter Real-World Study with Scalp-Specific Outcomes-IL PSO (Italian Landscape Psoriasis)Luciano Ibba, Sara Di Giulio, Piergiorgio Malagoli, et al.
Dermatology and Therapy|February 16, 2026
Real-World Efficacy of IL-23 Inhibitors in Psoriasis Affecting High-Impact Areas: Indirect Comparison of Tildrakizumab 200 mg, Risankizumab, and Guselkumab-IL PSO (Italian Landscape Psoriasis)Emanuele Trovato, Alessandra Cartocci, Francesca Gaiani, et al.
Dermatology and Therapy|July 3, 2025
Guselkumab Retention, Effectiveness, and Safety in Psoriasis: A 260-Week Real-World Multicenter Retrospective Study Exploring the Role of Concomitant PsA-IL PSO (Italian Landscape Psoriasis)Mario Valenti, Luciano Ibba, Sara Di Giulio, et al.
Journal of Clinical Medicine|May 27, 2023
Brodalumab for the Treatment of Moderate-to-Severe Psoriasis: An Expert Delphi Consensus StatementMaria Concetta Fargnoli, Federico Bardazzi, Luca Bianchi, et al.
Journal of Cutaneous Medicine and Surgery|March 17, 2026
Long-Term Outcomes of Secukinumab in Moderate-to-Severe Hidradenitis Suppurativa: A Multicentre Cohort StudyGianluca Avallone, Gabriele Roccuzzo, Luca Valtellini, et al.
Clinical and Experimental Dermatology|November 1, 2025
Cumulative clinical benefits of biologic treatments in patients with moderate-to-severe psoriasis: an Italian real-life experience - IL PSO (Italian Landscape Psoriasis)Diego Orsini, Luca Potestio, Maria Concetta Fargnoli, et al.
The Journal of Dermatological Treatment|February 6, 2026
Real-world effectiveness and safety of guselkumab in adult patients with facial and/or genital psoriasis: a 52-week analysis from the Italian multicentric GULLIVER studyClaudio Bonifati, Giuseppe Argenziano, Serena Lembo, et al.
BMC Health Services Research|September 7, 2021
A real-world economic analysis of biologic therapies for moderate-to-severe plaque psoriasis in Italy: results of the CANOVA observational longitudinal studyEmanuela Zagni, Luca Bianchi, Gabriella Fabbrocini, et al.
Pageof 26

Showing results (231-240 of 251) with videos related to

Sort By:
Pageof 26
Dermatology and Therapy|June 9, 2026
Real-World Long-Term Effectiveness and Safety of Secukinumab in Psoriasis: Up to 7 Years of Evidence from the Italian Landscape Psoriasis (IL PSO) Multicenter Retrospective StudyLuciano Ibba, Sara Di Giulio, Piergiorgio Malagoli, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|May 14, 2026
Treatment-associated phenotype switching between psoriasis and atopic dermatitisTiago Torres, Mario Valenti, Anna Balato, et al.
Dermatology and Therapy|March 17, 2026
Short-Term Effectiveness and Safety of Deucravacitinib in Psoriasis: A Multicenter Real-World Study with Scalp-Specific Outcomes-IL PSO (Italian Landscape Psoriasis)Luciano Ibba, Sara Di Giulio, Piergiorgio Malagoli, et al.
Dermatology and Therapy|February 16, 2026
Real-World Efficacy of IL-23 Inhibitors in Psoriasis Affecting High-Impact Areas: Indirect Comparison of Tildrakizumab 200 mg, Risankizumab, and Guselkumab-IL PSO (Italian Landscape Psoriasis)Emanuele Trovato, Alessandra Cartocci, Francesca Gaiani, et al.
Dermatology and Therapy|July 3, 2025
Guselkumab Retention, Effectiveness, and Safety in Psoriasis: A 260-Week Real-World Multicenter Retrospective Study Exploring the Role of Concomitant PsA-IL PSO (Italian Landscape Psoriasis)Mario Valenti, Luciano Ibba, Sara Di Giulio, et al.
Journal of Clinical Medicine|May 27, 2023
Brodalumab for the Treatment of Moderate-to-Severe Psoriasis: An Expert Delphi Consensus StatementMaria Concetta Fargnoli, Federico Bardazzi, Luca Bianchi, et al.
Journal of Cutaneous Medicine and Surgery|March 17, 2026
Long-Term Outcomes of Secukinumab in Moderate-to-Severe Hidradenitis Suppurativa: A Multicentre Cohort StudyGianluca Avallone, Gabriele Roccuzzo, Luca Valtellini, et al.
Clinical and Experimental Dermatology|November 1, 2025
Cumulative clinical benefits of biologic treatments in patients with moderate-to-severe psoriasis: an Italian real-life experience - IL PSO (Italian Landscape Psoriasis)Diego Orsini, Luca Potestio, Maria Concetta Fargnoli, et al.
The Journal of Dermatological Treatment|February 6, 2026
Real-world effectiveness and safety of guselkumab in adult patients with facial and/or genital psoriasis: a 52-week analysis from the Italian multicentric GULLIVER studyClaudio Bonifati, Giuseppe Argenziano, Serena Lembo, et al.
BMC Health Services Research|September 7, 2021
A real-world economic analysis of biologic therapies for moderate-to-severe plaque psoriasis in Italy: results of the CANOVA observational longitudinal studyEmanuela Zagni, Luca Bianchi, Gabriella Fabbrocini, et al.
Pageof 26